Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications

Area of Science:

• Infectious Diseases
• Pathology
• Critical Care Medicine

Background:

• Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19, a global health concern.
• COVID-19 presents with symptoms like fever, cough, and can lead to fatal complications such as acute kidney injury and acute respiratory distress syndrome.
• Cytokine storm in severe COVID-19 induces vascular endothelial injury, promoting hypercoagulability and disseminated intravascular coagulation.

Purpose of the Study:

• To summarize the mechanisms of hypercoagulability and thrombotic complications in severe COVID-19.
• To propose blood hypercoagulability and intravascular microthrombosis as critical development points in severe COVID-19.
• To highlight anticoagulation and anti-inflammatory therapy as potential treatment strategies.

Main Methods:

• Review of existing literature on COVID-19 pathophysiology.
• Analysis of autopsy findings in COVID-19 patients.
• Synthesis of evidence linking cytokine storm to hypercoagulability and thrombosis.

Main Results:

• Severe COVID-19 is characterized by systemic cytokine storm leading to vascular endothelial injury.
• This injury promotes a pro-thrombotic state, resulting in blood hypercoagulability and microthrombosis.
• Autopsy pathology confirms widespread intravascular coagulation in fatal COVID-19 cases.

Conclusions:

• Blood hypercoagulability and intravascular microthrombosis are key pathological events in severe COVID-19.
• Anticoagulation therapy may mitigate thrombotic complications.
• Anti-inflammatory treatments could address the underlying cytokine storm, offering a dual therapeutic approach.